Home > Insider Trading > Filing (0000899243-20-028430)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1701108	Spero Therapeutics Inc.	SPRO	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1720974	Ankit Mahadevia	C/O Spero Therapeutics, Inc. 675 Massachusetts Avenue, 14Th Floor Cambridge MA 02139	Ceo And President	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-10-13	14,367	$5.90	80,184	No	4	M	Direct
Common Stock	Disposition	2020-10-13	14,367	$14.28	65,817	No	4	S	Direct
Common Stock	Acquisiton	2020-10-14	105	$5.90	65,922	No	4	M	Direct
Common Stock	Disposition	2020-10-14	105	$14.25	65,817	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2020-10-13	14,367	$0.00	14,367	$5.90
Common Stock	Stock Option (Right to Buy)	Disposition	2020-10-14	105	$0.00	105	$5.90

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
504,441		2027-07-05	No	4	M	Direct
504,336		2027-07-05	No	4	M	Direct

Footnotes

All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 14,472 shares).
Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.
The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.25 to $14.52 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.